These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 33661541)

  • 1. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
    Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer.
    Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A
    Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and External Validation of a Prediction Model to Identify Candidates for Prostate Biopsy.
    Wagaskar VG; Lantz A; Sobotka S; Ratnani P; Parekh S; Falagario UG; Li L; Lewis S; Haines Iii K; Punnen S; Wiklund P; Tewari A
    Urol J; 2022 Nov; 19(5):379-385. PubMed ID: 34978065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
    J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
    Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
    Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
    Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.
    Truong M; Wang B; Gordetsky JB; Nix JW; Frye TP; Messing EM; Thomas JV; Feng C; Rais-Bahrami S
    Cancer; 2018 Jan; 124(2):278-285. PubMed ID: 28976544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study.
    Guo Y; Su K; Lu M; Liu X
    BMC Urol; 2023 May; 23(1):81. PubMed ID: 37138271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
    Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
    J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
    Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
    Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
    Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.